Hematopoietic stem cell transplantation (HSCT) is a useful treatment. In contrast to solid
organ transplantations, the use of ABO blood group mismatch is acceptable in HSCT …

Background ABO compatibility between donor and recipient is no necessary in allogeneic
hematopoietic stem cell transplantation (AHSCT). Incompatible transplantations can be …

Background Nucleotide mutations in the ABO gene may reduce the activity of
glycosyltransferase, resulting in lower levels of A or B antigen expression in red blood cells …

BACKGROUND Isohemagglutinins (anti‐A and anti‐B) mediate hemolytic transfusion
reactions, antibody‐mediated rejection of solid‐organ transplants, and delayed engraftment …

临床输血和输血相关免疫对移植物成活至关重要. 随着移植技术的发展, 实现了肝移植, 肾移植,
小肠移植, 肺移植, 子宫移植, 造血干细胞移植, 异种器官移植也在积极探索, 研究者也逐步对移植 …

ABO-group major incompatibility hematopoietic stem cell transplantation (HSCT) increases
the risk of delayed red cell engraftment and other immunological complications. In this study …

Introduction Myelofibrosis (MF) is a rare hematopoietic stem cell disorder progressing to
bone marrow (BM) failure or blast phase. Allogeneic hematopoietic cell transplantation …

Background aims ABO incompatibility does not hinder bone marrow transplantation (BMT),
but it has been associated with worse outcomes and additional adverse events. This study …

Objective ABO mismatch between donor and recipient occurs in 40% of allogeneic
hematopoietic stem cell transplantations (HCT). Different strategies have been described to …

Since the demonstration that hematopoietic cells are present in circulating blood, peripheral
blood stem cell transplantation (PBSCT) has become an area of interest. The invention of …